Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 4 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 36Pancreatic Neoplasms 26Rectal Neoplasms 15Esophageal Neoplasms 13Colonic Neoplasms 12Stomach Neoplasms 11Squamous Cell Carcinoma of Head and Neck 11Neoplasm Metastasis 8Gastrointestinal Neoplasms 8Esophageal Squamous Cell Carcinoma 7Adenocarcinoma Of Esophagus 7Neoplasms 6Head and Neck Neoplasms 5Carcinoma, Squamous Cell 5Carcinoma, Non-Small-Cell Lung 5Biliary Tract Neoplasms 5Carcinoma, Hepatocellular 4Advanced Solid Tumors 4Melanoma 3Liver Neoplasms 3Carcinoma, Renal Cell 3Adenocarcinoma 3Triple Negative Breast Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Ovarian Neoplasms 2Oropharyngeal Neoplasms 2Kidney Neoplasms 2Gastrointestinal Diseases 2Endometrial Neoplasms 2Carcinoma 2

Interventions

Cisplatin 3Cetuximab 3pembrolizumab 2zalutumumab 1temsirolimus 1osimertinib 1cobimetinib 1Taxes 1Sorafenib 1Radiotherapy 1Pemetrexed 1Paclitaxel 1Nivolumab 1Injections 1Fluorouracil 1Cilengitide 1Carboplatin 1Biological Products 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasms, Squamous Cell × Fluorouracil × Clear all
NCT00705016 2014-04-30

ADVANTAGE

Merck KGaA, Darmstadt, Germany

Phase 1/2 Completed
184 enrolled 20 charts

Neoplasm Metastasis, Recurrence, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡